Switzerland· 70648001
Paclitaxel-Albumin Accord 100 mg, Pulver zur Herstellung einer Infusionsdispersion
A paclitaxel product containing paclitaxelum, registered in Switzerland by Accord Healthcare AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Paclitaxel is registered in 16 of 19 countries.
Countries holding a registration under ATC L01CD01 (paclitaxel), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Paclitaxel · ATC L01CD01
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of paclitaxel costs, country by country.
Normalised to the WHO defined daily dose (15 mg), the median price runs from $0.61 in Czechia to $19.82 in Switzerland — a ×32 gap.
- Switzerland: $19.82 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Paclitaxel · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$19.82
- CZ Czechia$0.61
The record
At a glance
Swissmedic (Switzerland)- Active substance
- paclitaxelum
- Manufacturer
- Accord Healthcare AG
- Country
- Switzerland (CH)
- ATC code
- L01CD01
- ATC class
- Paclitaxel
- Defined daily dose
- 15 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680706480011Durchstf 1 StkCHF 210.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
651 interactions on record for paclitaxel.
Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Paclitaxel · interactions on record
651 records
- 41 severe
- 302 moderate
- 17 minor
- 291 info
Most severe, free to view
- SaquinavirJ05AE01severe
- IndinavirJ05AE02severe
- RitonavirJ05AE03severe
- NelfinavirJ05AE04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Paclitaxel in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAbraxane 100mg powder for dispersion for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- United StatesABRAXANEAbraxis BioScience, LLC
- BelgiumApacross 5 mg/mlSeacross Pharma (Europe)
- CzechiaABRAXANEBristol-Myers Squibb Pharma EEIG, Dublin
- FinlandAbraxaneOrifarm Oy
- GermanyApacrossSeacross Pharma (Europe) Ltd
- SwedenAbraxane 5 mg/ml Pulver till infusionsvätska, dispersionBristol-Myers Squibb Pharma EEIG
- FranceABRAXANE 5 mg/mL, poudre pour dispersion injectable pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Apacross, Bugvi
- Belgium · Apacross, Bugvi
- Bulgaria · Алсикроса, Паклитаксел Акорд
- Cyprus · Paclitaxel Accord, Paclitaxel Hospira
- Czechia · Alsicrosa, Paclitaxel Ebewe
- Germany · Apacross, Axitaxel
- Denmark · Apacross, Bugvi
- Estonia · Paclitaxel Accord, Paclitaxel Ebewe
- Spain · Apacross, Bugvi
- Finland · Apacross, Pacligen
- France · Bugvi, Paclitaxel Ahcl
- United Kingdom (Northern Ireland) · Apacross, Paclitaxel
- Greece · Biotaxel, Paclitaxel Hospira
- Croatia · Abutrax, Alsicrosa
- Hungary · Bugvi, Paclitaxel Accord
- Ireland · Apacross, Paclitaxel
- Iceland · Abraxane, Apexelsin
- Italy · Abutrax, Apacross
- Liechtenstein · Abraxane, Apexelsin
- Lithuania · Paclitaxel Accord, Paclitaxel Ebewe
- Luxembourg · Bugvi, Paclitaxel Accord Healthcare
- Latvia · Paclitaxel Accord, Paclitaxel Kabi
- Malta · Paclitaxel Accord Healthcare, Paclitaxel Hospira
- Netherlands · Abutrax, Apacross
- Norway · Abraxane, Apacross
- Poland · Paclitaxel Ebewe, Paclitaxel Kabi
- Portugal · Apacross, Paclitaxel Accord
- Romania · Bugvi, Paclitaxel Accord
- Sweden · Apacross, Bugvi
- Slovenia · Alsicrosa, Paclitaxin
- Slovakia · Paclitaxel Accord, Paclitaxel Kabi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e7d4cfe4-a213-4c29-93eb-b0084cefb577 GET /v1/drugs/e7d4cfe4-a213-4c29-93eb-b0084cefb577?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "paclitaxelum (paclitaxelum-albuminum) 100 mg",
"valid_from": "2026-07-01",
"limitations": "[{\"description\":\"<b>Adenokarzinom des Pankreas</b><br>\\nIn Kombination mit Gemcitabin, für die Erstlinienbehandlung von Patienten mit lokal fortgeschrittenem, nicht resezierbarem oder metastasiertem Adenokarzinom des Pankreas.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"22153.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-07-01\"},{\"description\":\"<b>Behandlung des metastasierenden Mammakarzinoms</b><br>\\nNach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Für die Behandlung mit Paclitaxel-Albumin Accord ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Originalpräparat oder ein anderes Generikum besteht.<br>\\nBehandlung des metastasierenden Mammakarzinoms nach Versagen einer Chemotherapie oder Rezidiv innert 6 Monaten nach adjuvanter Chemotherapie. In der Vortherapie muss ein Anthrazyklin enthalten gewesen sein, es sei denn, es bestand eine Kontraindikation. Die Therapie muss als Monotherapie verabreicht werden. Eine Kombination mit Biologika oder antihormoneller Therapie ist nicht möglich. Paclitaxel-Albumin Accord darf nicht als Alternative für andere Paclitaxel-Formulierungen verwendet werden, es sei denn die Behandlung mit anderen Paclitaxel-Formulierungen ist ungeeignet.<br>\\n<br>\\n\\n\\n\",\"costApproval\":null,\"indication\":\"22153.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-07-01\"}]",
"galenic_form": "Trockensub 100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2026-07-01",
"self_retention_pct": 10
}See everything about paclitaxel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.